218 filings
DEFA14A
OPTN
OptiNose Inc
26 Apr 24
Additional proxy soliciting materials
2:20pm
DEF 14A
OPTN
OptiNose Inc
Definitive proxy
26 Apr 24
2:18pm
8-K
OPTN
OptiNose Inc
25 Apr 24
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
7:41am
8-K
OPTN
OptiNose Inc
15 Mar 24
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
3:36pm
8-K
OPTN
OptiNose Inc
14 Mar 24
Entry into a Material Definitive Agreement
4:27pm
8-K
xwcu39
8 Mar 24
Entry into a Material Definitive Agreement
4:10pm
S-8
8lk 0elh0ei7bhidiop
7 Mar 24
Registration of securities for employees
4:32pm
8-K
wie31q50l
7 Mar 24
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
8-K
zzp wkxmz
23 Feb 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7:08am
8-K
y6wj ftcz7i
21 Dec 23
Entry into a Material Definitive Agreement
4:11pm
8-K
gl2vakpii9vst4
6 Dec 23
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
7:02am
8-K
40g5xyqb7qni3r 8l4x
9 Nov 23
Optinose Reports Third Quarter 2023 Financial Results
7:02am
EFFECT
mgys9 m1e0pgpf0ib
18 Aug 23
Notice of effectiveness
12:15am
UPLOAD
gqoj5drv2 a8
15 Aug 23
Letter from SEC
12:00am
CORRESP
fvsp6yggh4e2x4 z49i
15 Aug 23
Correspondence with SEC
12:00am
8-K
m5cluh7ek8wtzmx 8w
10 Aug 23
Optinose Reports Second Quarter 2023 Financial Results
7:02am